Oct 18, 2023 · Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and ...

On November 16, 2023, the Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, Inc.) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical ...

Enzalutamide (Xtandi®) is a type of hormone therapy for men with prostate cancer that has spread to other parts of the body (advanced prostate cancer). Enzalutamide works by blocking the effect of the hormone testosterone on prostate cancer cells.